JP2015529676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529676A5 JP2015529676A5 JP2015531646A JP2015531646A JP2015529676A5 JP 2015529676 A5 JP2015529676 A5 JP 2015529676A5 JP 2015531646 A JP2015531646 A JP 2015531646A JP 2015531646 A JP2015531646 A JP 2015531646A JP 2015529676 A5 JP2015529676 A5 JP 2015529676A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cells expressing
- cell antigen
- antigen
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 108010001441 Phosphopeptides Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201216649A GB201216649D0 (en) | 2012-09-18 | 2012-09-18 | Agents and methods |
| GB1216649.2 | 2012-09-18 | ||
| PCT/GB2013/052427 WO2014045022A2 (en) | 2012-09-18 | 2013-09-17 | Agents and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529676A JP2015529676A (ja) | 2015-10-08 |
| JP2015529676A5 true JP2015529676A5 (enExample) | 2016-12-22 |
Family
ID=47144453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531646A Withdrawn JP2015529676A (ja) | 2012-09-18 | 2013-09-17 | 作用物質および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150297745A1 (enExample) |
| EP (1) | EP2897642A2 (enExample) |
| JP (1) | JP2015529676A (enExample) |
| CN (1) | CN104812413A (enExample) |
| AU (1) | AU2013319980C1 (enExample) |
| CA (1) | CA2885133A1 (enExample) |
| GB (1) | GB201216649D0 (enExample) |
| WO (1) | WO2014045022A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| WO2016023040A1 (en) * | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| EP3903818A1 (en) * | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| JP2017141172A (ja) * | 2016-02-08 | 2017-08-17 | 日本全薬工業株式会社 | 抗イヌｃｄ７０モノクローナル抗体 |
| WO2018183520A1 (en) * | 2017-03-28 | 2018-10-04 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
| CA3096844A1 (en) * | 2018-05-15 | 2019-11-21 | Merck Patent Gmbh | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| ES2961791T3 (es) * | 2018-12-19 | 2024-03-13 | Humabs Biomed Sa | Anticuerpos que neutralizan el virus de la hepatitis B y usos de los mismos |
| LT4285929T (lt) | 2018-12-20 | 2026-01-12 | Humabs Biomed Sa | Kompleksinė hbv terapija |
| KR20220044904A (ko) | 2019-05-31 | 2022-04-12 | 알렉소 온콜로지 인크. | 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법 |
| WO2021021963A1 (en) * | 2019-07-29 | 2021-02-04 | Deverra Therapeutics Inc. | Nk cell composition and preparations for immunotherapy and methods for their production |
| CN114845710A (zh) | 2019-11-27 | 2022-08-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| BR112023022774A2 (pt) | 2021-05-13 | 2024-01-02 | Alx Oncology Inc | Terapias de combinação para tratamento de câncer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0615451T3 (da) * | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| EP0659438A1 (en) * | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
| CA2240834C (en) * | 1995-12-22 | 2013-12-03 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| JP4472351B2 (ja) * | 2002-03-01 | 2010-06-02 | イミューノメディクス、インコーポレイテッド | インターナライジング抗ｃｄ７４抗体およびその使用方法 |
| US9402916B2 (en) * | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| EP2827889A1 (en) * | 2012-03-19 | 2015-01-28 | Deutsches Krebsforschungszentrum | B-cell receptor complex binding proteins containing t-cell epitopes |
-
2012
- 2012-09-18 GB GB201216649A patent/GB201216649D0/en not_active Ceased
-
2013
- 2013-09-17 CA CA 2885133 patent/CA2885133A1/en not_active Abandoned
- 2013-09-17 AU AU2013319980A patent/AU2013319980C1/en not_active Expired - Fee Related
- 2013-09-17 EP EP13782809.1A patent/EP2897642A2/en not_active Withdrawn
- 2013-09-17 JP JP2015531646A patent/JP2015529676A/ja not_active Withdrawn
- 2013-09-17 US US14/428,449 patent/US20150297745A1/en not_active Abandoned
- 2013-09-17 WO PCT/GB2013/052427 patent/WO2014045022A2/en not_active Ceased
- 2013-09-17 CN CN201380059696.9A patent/CN104812413A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Injectable supramolecular hydrogel for locoregional immune checkpoint blockade and enhanced cancer chemo-immunotherapy | |
| Vermaelen | Vaccine strategies to improve anti-cancer cellular immune responses | |
| Cuzzubbo et al. | Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments | |
| Bijker et al. | Design and development of synthetic peptide vaccines: past, present and future | |
| Melssen et al. | Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer | |
| Lichty et al. | Going viral with cancer immunotherapy | |
| Wu et al. | Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation | |
| JP5539460B2 (ja) | 癌免疫治療のための組成物および方法 | |
| Sharma et al. | Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors | |
| Li et al. | TLR agonists as adjuvants for cancer vaccines | |
| US12090194B2 (en) | Medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| Maynard et al. | Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication | |
| den Brok et al. | Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction | |
| Srivastava et al. | SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines | |
| CN106687138B (zh) | 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物 | |
| CA2840959A1 (en) | Vaccine composition | |
| Wang et al. | Therapeutic vaccines for cancer immunotherapy | |
| JP2015533376A5 (enExample) | ||
| Lopez et al. | Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection | |
| JP2025085695A (ja) | 既存の微生物免疫を利用した癌処置 | |
| Qiao et al. | A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice | |
| James et al. | Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells | |
| JP2020528449A5 (enExample) | ||
| Kamel et al. | Advancement insights in cancer vaccines: mechanisms, types, and clinical applications | |
| JP6836829B2 (ja) | 核内受容体リガンドを含む免疫誘導促進用組成物及びワクチン医薬組成物 |